Galaxy Next Generation Stock (OTC:GAXY), Trade Ideas

Galaxy Next Generation Inc is a distributor of interactive learning technology hardware and software that allows the presenter and participant to engage in a fully collaborative instructional environment. Its products include its own private-label interactive touch screen panel as well as numerous other national and international branded peripheral and communication devices.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Penny Stocks

Small Cap

Markets

General

ADDYY

AKZOY

BNPQY

CYDVF

DANOY

DMGGF

DTEGY

ETHE

FMCC

FNMA

GAXY

GBTC

AMERICAN LITHIUM CORP ORD by American Lithium Corp.

LIACF

NGLOY

NLST

NVNXF

RHHBY

TCNNF

VRNOF

VYGVF

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

As the year drew to a close, the OTC Markets realized an expected slump in trading volume compared to November; however, trading is still up compared to previous years.

These OTC Securities Had the Most Trading Activity in December

Cannabis

Commodities

DSGT

ETCG

GDLC

GTBIF

GLDLF

GPVRF

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Dollar volume on the OTCQX Market rose roughly 8.6% in August from July, with much of that increase coming from heightened trading activity in a select number of industries. 

Traders Piled Into Cannabis, Crypto, and Gold Securities On OTC Markets In August

Biotech

Long Ideas

Short Ideas

Emerging Markets

Specialty ETFs

Eurozone

Health Care

Global

Trading Ideas

ETFs

ADRNY

AXAHY

CYDY

EXPGY

HEINY

IMBBY

IPIX

JBSAY

KBLB

TOMDF

MDNAF

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

The COVID-19 pandemic has led to dramatic changes in market behavior, as traders and investors try to grapple with the short-term and long-term implications of a pandemic.

The Spread of COVID-19 Has Caused Massive Volume Spikes In Securities On OTC Markets

GALAXY NEXT GENERATION by Galaxy Next Generation, Inc.

Galaxy Next Generation Inc

Options

Foot Locker Option Alert: Jan, 2026 $40 Calls Sweep (10) near the Ask: 347 @ $2.351 vs 160 OI; Earnings 5/17 Before Open [est] Ref=$21.9

<p>Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) in the last three months.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Zoetis, presenting an average target of $220.0, a high estimate of $260.00, and a low estimate of $195.00. Highlighting a 5.58% decrease, the current average has fallen from the previous average price target of $233.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713888087_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Zoetis by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$195.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$255.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Zoetis. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zoetis compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Zoetis's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Capture valuable insights into Zoetis's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ZTS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Zoetis analyst ratings.</strong></a></p>
<h2>About Zoetis</h2>
<p>Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.</p>
<h3>Financial Insights: Zoetis</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Zoetis's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>8.48%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Zoetis's net margin is impressive, surpassing industry averages. With a net margin of <strong>23.72%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Zoetis's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>10.42%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Zoetis's ROA excels beyond industry benchmarks, reaching <strong>3.7%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Zoetis's debt-to-equity ratio surpasses industry norms, standing at <strong>1.35</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Zoetis Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

<p>Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) has outperformed the market over the past 20 years by 20.91% on an annualized basis producing an average annual return of 28.78%. Currently, Netflix has a market capitalization of $239.96 billion. </p>
<p><strong>Buying $100 In NFLX:</strong> If an investor had bought $100 of NFLX stock 20 years ago, it would be worth <strong>$15,316.97</strong> today based on a price of $556.89 for NFLX at the time of writing.</p>
<h3>Netflix's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713888083_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


NFLX

$100 Invested In This Stock 20 Years Ago Would Be Worth $15,000 Today

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Uber Technologies</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with UBER, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 21 uncommon options trades for Uber Technologies.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 52% bullish and 38%, bearish.</p>
<p>Out of all of the special options we uncovered, 8 are puts, for a total amount of $1,181,035, and 13 are calls, for a total amount of $565,714.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $32.5 to $95.0 for Uber Technologies over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Uber Technologies options trades today is 3029.33 with a total volume of 9,637.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Uber Technologies's big money trades within a strike price range of $32.5 to $95.0 over the last 30 days.</p>
<h3>Uber Technologies 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713888068_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>UBER</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$6.05</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$72.50</td>
<td>$694.2K</td>
<td>1.0K</td>
<td>1.1K</td>
</tr>
<tr>
<td>UBER</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/17/24</td>
<td>$1.35</td>
<td>$1.31</td>
<td>$1.33</td>
<td>$65.00</td>
<td>$146.5K</td>
<td>13.4K</td>
<td>1.1K</td>
</tr>
<tr>
<td>UBER</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$37.8</td>
<td>$37.5</td>
<td>$37.8</td>
<td>$32.50</td>
<td>$132.3K</td>
<td>183</td>
<td>0</td>
</tr>
<tr>
<td>UBER</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$26.45</td>
<td>$26.2</td>
<td>$26.2</td>
<td>$95.00</td>
<td>$115.2K</td>
<td>180</td>
<td>44</td>
</tr>
<tr>
<td>UBER</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$4.8</td>
<td>$4.75</td>
<td>$4.8</td>
<td>$72.50</td>
<td>$69.6K</td>
<td>1.4K</td>
<td>50</td>
</tr>
</tbody>
</table>
</p>
<h3>About Uber Technologies</h3>
<p>Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides "aerial ride-sharing." Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 150 million users who order rides or food at least once a month.</p>
<p>In light of the recent options history for Uber Technologies, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Uber Technologies</h3>
<ul>
<li>With a trading volume of 5,585,294, the price of UBER is up by 1.32%, reaching $69.89.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 15 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Uber Technologies</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $92.6.</p>
<ul>
<li>An analyst from Needham downgraded its action to Buy with a price target of $90. </li>
<li>Reflecting concerns, an analyst from JMP Securities lowers its rating to Market Outperform with a new price target of $85.</li>
<li>An analyst from Tigress Financial persists with their Buy rating on Uber Technologies, maintaining a target price of $96. </li>
<li>An analyst from MoffettNathanson has revised its rating downward to Buy, adjusting the price target to $92. </li>
<li>An analyst from Jefferies has decided to maintain their Buy rating on Uber Technologies, which currently sits at a price target of $100. </li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Uber Technologies options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


UBER

Behind the Scenes of Uber Technologies's Latest Options Trends

<p>Financial giants have made a conspicuous bearish move on UnitedHealth Group. Our analysis of options history for UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) revealed 11 unusual trades.</p>
<p>Delving into the details, we found 36% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $117,096, and 7 were calls, valued at $650,216.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $470.0 and $600.0 for UnitedHealth Group, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in UnitedHealth Group's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to UnitedHealth Group's substantial trades, within a strike price spectrum from $470.0 to $600.0 over the preceding 30 days.</p>
<h3>UnitedHealth Group 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713888062_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$12.45</td>
<td>$12.15</td>
<td>$12.45</td>
<td>$485.00</td>
<td>$435.7K</td>
<td>11</td>
<td style="text-align: right;">381</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$3.0</td>
<td>$2.98</td>
<td>$2.98</td>
<td>$495.00</td>
<td>$45.3K</td>
<td>621</td>
<td style="text-align: right;">686</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$10.9</td>
<td>$10.75</td>
<td>$10.75</td>
<td>$490.00</td>
<td>$43.0K</td>
<td>1.2K</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$40.85</td>
<td>$40.25</td>
<td>$40.25</td>
<td>$500.00</td>
<td>$36.2K</td>
<td>1.7K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$119.3</td>
<td>$115.0</td>
<td>$115.0</td>
<td>$600.00</td>
<td>$34.5K</td>
<td>70</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
</p>
<h3>About UnitedHealth Group</h3>
<p>UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 53 million members globally, including 5 million outside the U.S. as of mid-2023. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.</p>
<p>After a thorough review of the options trading surrounding UnitedHealth Group, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of UnitedHealth Group</h3>
<ul>
<li>With a volume of 1,275,257, the price of UNH is down -0.56% at $488.5. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 80 days.</li>
</ul>
<h3>Expert Opinions on UnitedHealth Group</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $564.4.</p>
<ul>
<li>An analyst from Morgan Stanley persists with their Overweight rating on UnitedHealth Group, maintaining a target price of $584. </li>
<li>An analyst from Barclays has decided to maintain their Overweight rating on UnitedHealth Group, which currently sits at a price target of $560. </li>
<li>Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $591.</li>
<li>Consistent in their evaluation, an analyst from Deutsche Bank keeps a Buy rating on UnitedHealth Group with a target price of $562. </li>
<li>Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for UnitedHealth Group, targeting a price of $525. </li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest UnitedHealth Group options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Check Out What Whales Are Doing With UNH

<p>Throughout the last three months, 5 analysts have evaluated Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Medpace Hldgs and provided 12-month price targets. The average target is $437.0, accompanied by a high estimate of $480.00 and a low estimate of $395.00. This current average reflects an increase of 26.12% from the previous average price target of $346.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713888061_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A comprehensive examination of how financial experts perceive Medpace Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$450.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Justin Bowers</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$395.00</td>
<td>-</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$480.00</td>
<td>$452.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$452.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$408.00</td>
<td>$312.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Medpace Hldgs. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Medpace Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Medpace Hldgs's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Medpace Hldgs's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MEDP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Medpace Hldgs analyst ratings.</strong></a></p>
<h2>Delving into Medpace Hldgs's Background</h2>
<p>Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.</p>
<h3>Medpace Hldgs: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Medpace Hldgs displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>26.47%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Medpace Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>15.7%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Medpace Hldgs's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>15.2%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Medpace Hldgs's ROA excels beyond industry benchmarks, reaching <strong>4.98%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.25</strong>, Medpace Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MEDP

Decoding 5 Analyst Evaluations For Medpace Hldgs

<p>Deep-pocketed investors have adopted a bullish approach towards Coinbase Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in COIN usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 71 extraordinary options activities for Coinbase Glb. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 47% leaning bullish and 45% bearish. Among these notable options, 12 are puts, totaling $2,194,385, and 59 are calls, amounting to $5,336,332.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $520.0 for Coinbase Glb over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Coinbase Glb stands at 1007.28, with a total volume reaching 61,204.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Coinbase Glb, situated within the strike price corridor from $100.0 to $520.0, throughout the last 30 days.</p>
<h3>Coinbase Glb Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713888056_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>COIN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/03/24</td>
<td>$25.15</td>
<td>$24.15</td>
<td>$24.15</td>
<td>$247.50</td>
<td>$1.7M</td>
<td>37</td>
<td>1</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/03/24</td>
<td>$16.5</td>
<td>$15.45</td>
<td>$16.5</td>
<td>$240.00</td>
<td>$1.6M</td>
<td>633</td>
<td>1.1K</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$19.1</td>
<td>$18.6</td>
<td>$18.6</td>
<td>$250.00</td>
<td>$548.7K</td>
<td>1.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$25.2</td>
<td>$23.9</td>
<td>$24.5</td>
<td>$450.00</td>
<td>$245.0K</td>
<td>1.3K</td>
<td>250</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/03/24</td>
<td>$15.55</td>
<td>$15.2</td>
<td>$15.2</td>
<td>$240.00</td>
<td>$152.0K</td>
<td>633</td>
<td>7.8K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Coinbase Glb</h3>
<p>Founded in 2012, Coinbase is the leading cryptocurrency exchange platform in the United States. The company intends to be the safe and regulation-compliant point of entry for retail investors and institutions into the cryptocurrency economy. Users can establish an account directly with the firm, instead of using an intermediary, and many choose to allow Coinbase to act as a custodian for their cryptocurrency, giving the company breadth beyond that of a traditional financial exchange. While the company still generates the majority of its revenue from transaction fees charged to its retail customers, Coinbase uses internal investment and acquisitions to expand into adjacent businesses, such as prime brokerage and data analytics.</p>
<h3>Coinbase Glb's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,674,492, the price of COIN is up by 3.18%, reaching $233.05.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 9 days from now.</li>
</ul>
<h3>What The Experts Say On Coinbase Glb</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $248.0.</p>
<ul>
<li>Maintaining their stance, an analyst from Compass Point continues to hold a Buy rating for Coinbase Glb, targeting a price of $325. </li>
<li>Consistent in their evaluation, an analyst from Piper Sandler keeps a Neutral rating on Coinbase Glb with a target price of $245. </li>
<li>Consistent in their evaluation, an analyst from B of A Securities keeps a Underperform rating on Coinbase Glb with a target price of $110. </li>
<li>An analyst from JMP Securities has decided to maintain their Market Outperform rating on Coinbase Glb, which currently sits at a price target of $320. </li>
<li>An analyst from Canaccord Genuity has revised its rating downward to Buy, adjusting the price target to $240. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Coinbase Glb, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


COIN

What the Options Market Tells Us About Coinbase Glb

<p>9 analysts have expressed a variety of opinions on Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Procter &amp; Gamble, revealing an average target of $170.11, a high estimate of $182.00, and a low estimate of $160.00. This current average reflects an increase of 2.71% from the previous average price target of $165.62. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713888052_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Procter &amp; Gamble. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Steve Powers</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$171.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Kaumil Gajrawala</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$182.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Steve Powers</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$172.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Bill Chappell</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Jason English</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$168.00</td>
<td>-</td>
</tr>
<tr>
<td>Bill Chappell</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$160.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Procter &amp; Gamble. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Procter &amp; Gamble compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Procter &amp; Gamble's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Procter &amp; Gamble's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PG/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Procter &amp; Gamble analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Procter &amp; Gamble</h2>
<p>Since its founding in 1837, Procter &amp; Gamble has become one of the world's largest consumer product manufacturers, generating more than $80 billion in annual sales. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. P&amp;G sold its last remaining food brand, Pringles, to Kellogg in calendar 2012. Sales outside its home turf represent around 53% of the firm's consolidated total.</p>
<h3>Procter &amp; Gamble's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Procter &amp; Gamble showcased positive performance, achieving a revenue growth rate of <strong>0.63%</strong> as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Procter &amp; Gamble's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>18.25%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Procter &amp; Gamble's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>7.6%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Procter &amp; Gamble's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>3.07%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Procter &amp; Gamble's debt-to-equity ratio is below the industry average. With a ratio of <b>0.65</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Closer Look at 9 Analyst Recommendations For Procter & Gamble

<p>In the preceding three months, 6 analysts have released ratings for FIGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for FIGS, presenting an average target of $5.93, a high estimate of $11.00, and a low estimate of $4.25. A decline of 22.18% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713888045_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive FIGS is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$4.25</td>
<td>$4.85</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$4.50</td>
<td>$8.50</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$4.85</td>
<td>$6.75</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$6.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$11.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to FIGS. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of FIGS compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for FIGS's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of FIGS's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FIGS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on FIGS analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering FIGS: A Closer Look</h2>
<p>FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company markets and sells its products in the United States. Sales are generated through the Company's digital platforms.</p>
<h3>FIGS: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> FIGS's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of <strong>0.01%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> FIGS's net margin excels beyond industry benchmarks, reaching <strong>6.9%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> FIGS's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>2.73%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.19%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.13</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FIGS

Expert Outlook: FIGS Through The Eyes Of 6 Analysts

<p>In the latest quarter, 6 analysts provided ratings for Generac Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $135.0, with a high estimate of $150.00 and a low estimate of $118.00. This upward trend is apparent, with the current average reflecting a 6.44% increase from the previous average price target of $126.83.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713888035_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The perception of Generac Hldgs by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chip Moore</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$129.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>J.B. Lowe</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$128.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Chip Moore</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Neutral</td>
<td>$118.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Generac Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Generac Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Generac Hldgs's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Generac Hldgs's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GNRC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Generac Hldgs analyst ratings.</strong></a></p>
<h2>About Generac Hldgs</h2>
<p>Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.</p>
<h3>Breaking Down Generac Hldgs's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Generac Hldgs's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of <strong>1.38%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Generac Hldgs's net margin excels beyond industry benchmarks, reaching <strong>9.02%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Generac Hldgs's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.08%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Generac Hldgs's ROA excels beyond industry benchmarks, reaching <strong>1.87%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.74</strong>, Generac Hldgs faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GNRC

A Closer Look at 6 Analyst Recommendations For Generac Hldgs

<p><strong>Cyngn Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares are trading higher Tuesday after the company announced that it has been chosen to supply its DriveMod Tuggers for industrial automation to <strong>John Deere&#8217;s</strong> <a href="https://www.benzinga.com/pressreleases/24/04/n38375211/cyngn-joins-john-deere-supply-base">operation in Dubuque, Iowa.</a></p>
<p><strong>The Details:</strong></p>
<p>&#8220;We are thrilled to be working with Deere, a company that has a long history of producing cutting-edge technology that yields amazing products for its customers,&#8221; said Cyngn&#8217;s CEO, <strong>Lior Tal</strong>. &#8220;Our product offering achieves immense validation from being selected by a world-leading brand like Deere.&#8221;</p>
<p>Cyngn shares are moving on heavy trading volume following the announcement. According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, more than 160 million shares have already been traded in the session, compared to the stock&#8217;s 100-day average of just over 10 million shares.</p>
<p>Cyngn develops and deploys scalable, differentiated AI-powered autonomous vehicles and data solutions based in Menlo Park, CA.</p>
<p><em>Related News: </em><a href="https://www.benzinga.com/news/24/04/38360358/whats-going-on-with-luxury-ev-maker-lucids-stock"><em>What&#8217;s Going On With Luxury EV-Maker Lucid&#8217;s Stock?</em></a></p>
<h2 class="wp-block-heading"><strong>How To Buy CYN Stock: </strong></h2>
<p>By now you're likely curious about how to participate in the market for Cyngn &#8211; be it to purchase shares, or even attempt to bet against the company.</p>
<p>Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. </p>
<p>In the the case of Cyngn, which is trading at $0.23 as of publishing time, $100 would buy you 434.78 shares of stock.</p>
<p>If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.</p>
<p><strong>CYN Price Action:</strong> According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Cyngyn shares are up 59% at 19 cents at the time of publication Tuesday.</p>
<p><em>Image: Pete Linforth from Pixabay</em></p>


Movers

Why AI-Powered Vehicle Supplier Cyngn's Stock Is Driving Higher

<p>Ratings for Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $39.6, a high estimate of $44.00, and a low estimate of $35.00. Marking an increase of 38.12%, the current average surpasses the previous average price target of $28.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713888024_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of Blue Bird among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craig Irwin</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Adam Seiden</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Craig Irwin</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Blue Bird. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Blue Bird compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Blue Bird's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Blue Bird's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BLBD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Blue Bird analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Blue Bird</h2>
<p>Blue Bird Corp is an American bus manufacturing company. It has its operations in two segments. The Bus segment involves the design, engineering, manufacture and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. It carries its operations in the United States, Canada, and the rest of the world. The majority of its sales are derived from the United States through its bus manufacturing business.</p>
<h3>Financial Milestones: Blue Bird's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Blue Bird's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>34.75%</strong> as of 31 December, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Blue Bird's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>8.23%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Blue Bird's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>45.25%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Blue Bird's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>6.16%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Blue Bird's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.8</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BLBD

Deep Dive Into Blue Bird Stock: Analyst Perspectives (5 Ratings)

WIIM

Ryder System shares are trading higher following a Q1 earnings beat and narrowed its 2024 guidance.

RIVN

Rivian Automotive Option Alert: Fri $9.5 Calls Sweep (76) near the Ask: 7357 @ $0.153 vs 9904 OI; Earnings 5/7 After Close Ref=$9.15

<p>Wells Fargo  analyst Eric Luebchow   maintains Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) with a Equal-Weight and lowers the price target from $44 to $40.</p>


Price Target

Wells Fargo Maintains Equal-Weight on Verizon Communications, Lowers Price Target to $40

<p>A glimmer of hope has emerged for creditors of the defunct <a href="https://www.benzinga.com/markets/cryptocurrency/23/11/35920364/from-ashes-to-redemption-bitcoin-exchange-mt-gox-emerges-from-ruins-to-honor-debts">Mt. Gox crypto exchange</a>, with some creditors having reportedly received updates on their claims.</p>
<p><strong>What Happened</strong>: The updates include the number of <strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) the creditors receive and, in some cases, even repayment dates, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-04-23/failed-mt-gox-s-9-billion-of-bitcoin-btc-closer-to-being-disbursed?embedded-checkout=true">reported</a>.</p>
<p>Mt. Gox, once the world&#8217;s leading Bitcoin exchange, suffered a <a href="https://www.benzinga.com/markets/cryptocurrency/23/09/34735847/bitcoin-climbs-on-mt-gox-rumors-trading-firm-expects-imminent-drop-to-22k">devastating hack in 2011</a> and subsequently filed for bankruptcy in 2014. </p>
<p>Since then, creditors have been in limbo, unsure of when or if they would ever see their lost funds again.</p>
<p>The recent updates, while lacking specifics from Mt. Gox officials themselves, are seen as a positive development. </p>
<p>&#8220;This is the first time we&#8217;ve seen an update such as this on repayment status,&#8221; said <strong>Brian Dixon</strong>, CEO of <strong>Off the Chain Capital</strong>, a firm that purchased Mt. Gox claims. </p>
<p>He confirmed receiving a repayment date, though declined to disclose it publicly.</p>
<p>While some details are emerging, key questions remain. </p>
<p><strong>Adam Back</strong>, CEO of <strong>Blockstream</strong>, another creditor, received updates on the number of tokens he&#8217;ll receive but is still waiting for repayment dates. </p>
<p>The potential impact on the Bitcoin price is also a concern. With Mt. Gox holding a massive $9.2 billion Bitcoin hoard, a large-scale sell-off by creditors could trigger price fluctuations.</p>
<p>The trustee overseeing the Mt. Gox wind-down process has previously indicated that creditors can expect a series of lump-sum payments throughout the year. </p>
<p>With these recent updates, it appears progress is finally being made on returning the lost funds.</p>
<p><strong>What&#8217;s Next</strong>: The Mt. Gox saga highlights the risks and uncertainties associated with the cryptocurrency market. </p>
<p>However, it also demonstrates the resilience of the industry and its ongoing efforts to improve security and transparency.</p>
<p>If you&#8217;re interested in staying informed about the future of digital assets and navigating the evolving crypto landscape, consider attending the Benzinga <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38365501/crypto-greed-almost-at-all-time-high-but-prices-are-not-warns-trader-this-cycle-is-kinda-c" target="_blank" rel="noreferrer noopener">Crypto ‘Greed Almost At All-Time High, But Prices Are Not' Warns Trader: ‘This Cycle Is Kinda Cooked'</a></em></p>
<p><em>Image created using artificial intelligence with Midjourney.</em></p>


$BTC

Mt. Gox Creditors See Repayment Light At The End Of The Tunnel

NVDA

NXPI

Shares of semiconductor stocks are trading higher amid a continued rebound following Friday's drop.

<p>Wells Fargo  analyst Gary Mobley   maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Overweight and lowers the price target from $110 to $95.</p>


Wells Fargo Maintains Overweight on ON Semiconductor, Lowers Price Target to $95

Politics

ORCL

PINS

Bytedance Says It Sent TikTok Lite Risk-Assessment Report To EU After EU Gave Co 24 Hours To Produce The Document

<p>Wells Fargo  analyst Steven Cahall   maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Overweight and raises the price target from $128 to $141.</p>


Wells Fargo Maintains Overweight on Walt Disney, Raises Price Target to $141

Galaxy Next Generation bags repeat orders for ~$100k in Ohio

Galaxy Next Generation provides clarity on outstanding convertible notes

Press Releases

Galaxy Next Generation Partners with AVI Systems, the Largest Global Audiovisual Services Provider

Galaxy Next Generation Issues Shareholder Update after Q3 FY 2023 Earnings Report

Galaxy Next Generation Gains $200,000+ Revenue from Northeast Ohio School District

Galaxy Next Generation Receives Two Additional Purchase Orders from Ohio School District

Galaxy Next Generation to Host Shareholder Update Call on Thursday, August 10, 2023